NICE and the challenge of cancer drugsBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b478 (Published 06 February 2009) Cite this as: BMJ 2009;338:b478
In the rush to get this fast tracked article to print (BMJ 2009;338:b67, doi:10.1136/bmj.b67) the author missed several errors. In the second paragraph, the number of cancer drugs provisionally rejected by the National Institute for Health and Clinical Excellence on grounds of their high cost per QALY (quality adjusted life year) should be seven not six, and in the seventh paragraph the second drug that would qualify for funding should be permetrexed for lung cancer [not “lapatinib for breast cancer”]. In the table, fludarabine is first line treatment for chronic lymphocytic leukaemia [not “leukaemia lymphocytic”]; the condition listed for lenalidomide should be multiple myeloma [not “multiple myeloid leukaemia”]; and the figures for cost per patient are £000s not £s.
Cite this as: BMJ 2009;338:b478